会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS
    • 作为治疗化合物的吡咯并吡啶及其衍生物
    • WO2006067466A3
    • 2007-07-05
    • PCT/GB2005005011
    • 2005-12-22
    • WELLCOME TRUST LTDSPRINGER CAROLINE JOYNICULESCU-DUVAZ IONROMAN VELA ESTEBANGILL ADRIAN LIAMTAYLOR RICHARD DAVIDMARAIS RICHARD MALCOLM
    • SPRINGER CAROLINE JOYNICULESCU-DUVAZ IONROMAN VELA ESTEBANGILL ADRIAN LIAMTAYLOR RICHARD DAVIDMARAIS RICHARD MALCOLM
    • C07D241/20A61K31/444A61K31/497A61P35/00C07D213/74C07D317/46C07D319/18C07D321/10C07D401/04C07D401/12C07D403/04C07D403/12C07D409/12C07D413/12C07D417/12
    • C07D213/74C07D241/20C07D317/46C07D319/18C07D321/10C07D401/04C07D401/12C07D403/04C07D403/12C07D409/12C07D413/12C07D417/12
    • The present invention pertains to certain pyrazines and pyridines, and dervatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: (I) wherein: Q is independently -N= or -CH=; one of R P2 and R P3 is independently a group of the formula -J 1 -L 1 -Z; wherein: if Q is -N=, then -J 1 -L 1 -Z is independently: -NH-Z; -O-Z; or S-Z; if Q is -CH=, then -J 1 -L 1 -Z is independently: -NH-(CH 2 ) n -Z, wherein n is independently 0 or 1; -O-Z; or -S-Z; Z is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; the other of R P2 and R P3 is independently -H, -NHR N1 , or -NHC(=O)R N2 ; wherein: R N1 , if present, is independently -H or aliphatic saturated C 1-4 alkyl; R N2 , if present, is independently -H or aliphatic saturated C 1-4 alkyl; one of R P5 and R P6 is independently a group of the formula -W-Y; wherein: W is independently: a covalent bond; -NR N4 -, -O-, -S-, -C(=O)-, -CH 2 -; -NR N4 -CH 2 -, -O-CH 2 -, -S-CH 2 -, -C(=O)-CH 2 -, -(CH 2 ) 2 -; -CH 2 -NR N4 -, -CH 2 -O-, -CH 2 -S-, or -CH 2 -C(=O)-; wherein R N4 , if present, is independently -H or aliphatic saturated C 1-4 alkyl; Y is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; the other of R P5 and R P6 is independently -H; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, e.g., both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.
    • 本发明涉及某些吡嗪和吡啶及其衍生物,其特别是抑制RAF(例如,B RAF)活性,抑制细胞增殖,治疗癌症等,更具体地涉及下式的化合物:(I )其中:Q独立地为-N =或-CH =; R“P2”和“R”中的一个独立地是式-I-1-L-1-Z的基团 ; 其中:如果Q是-N =,则-J 1 -L 1 -Z独立地是:-NH-Z; -O-Z; 或S-Z; 如果Q是-CH =,则-J 1 -L 1 -Z独立地是:-NH-(CH 2 CH 2) n -Z,其中n独立地为0或1; -O-Z; 或-S-Z; Z独立地为:C 6-14芳烷基,C 5-14杂芳基,C 3-12碳环,C 3-12 杂环; 并且独立地是未取代的或取代的; R 2 P2和R 3 P 2中的另一个独立地为-H,-NHR 1 N 1或-NHC(= O)R N 2 ; 其中:如果存在,R“独立地为-H或脂族饱和C 1-4烷基; 如果存在,则R 2独立地为-H或脂族饱和C 1-4烷基; R 5 P 5和R 6 P 6中的一个独立地是式-W-Y的基团; 其中:W独立地为:共价键; -NR N - , - O - , - S - , - C(= O) - , - CH 2 - 。 -NR N4 - CH 2 - , - O-CH 2 - , - S-CH 2 - , - -C(= O)-CH 2 - , - (CH 2)2 - ; - (CH 2)2 - -CH 2,-NR N 4 - , - CH 2 -O - , - CH 2 -S-, 或-CH 2 -C(= O) - ; 其中R“N4”(如果存在)独立地是-H或脂族饱和C 1-4烷基; Y独立地为:C 6-14碳芳基,C 5-14杂芳基,C 3-12碳环,C 3-12 杂环基; 并且独立地是未取代的或取代的; R“P5”和“R”P6中的另一个独立地是-H; 酰胺,酯,醚,N-氧化物,化学保护形式及其前体药物。 本发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在体外和体内两者抑制RAF(例如B-RAF)活性抑制受体酪氨酸激酶(RTK)的用途, 活性,抑制细胞增殖,以及通过抑制RAF,RTK等改善增殖条件如癌症(例如结肠直肠癌,黑素瘤)等的疾病和病症的治疗。